Related Experiment Video
Updated: Apr 26, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Pharmacological upregulation of PGC1α in oligodendrocytes: implications for Huntington's Disease
Zhongmin Xiang1, Dimitri Krainc1
1MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Abstract:
The coactivator PGC1α plays a role in the transcriptional regulation of energy metabolism and its deficiency has been implicated in abnormalities of myelination and oligodendrocyte differentiation in Huntington's disease (HD). In an effort to activate PGC1α in oligodendrocytes, we found that overexpression of SIRT1 or treatment with resveratrol (RSV) and SRT1720 upregulated PGC1α expression and increased oligodendrocyte differentiation. Interestingly, in oligodendrocytes expressing mutant huntingtin, SRT1720 but not RSV was able to restore PGC1α expression and the differentiation. These results suggest that pharmacological activation of PGC1α in oligodendrocytes by SRT1720 may provide a therapeutic opportunity for correction of deficient myelination in HD.
More Related Videos
11:11Preparation of Rat Oligodendrocyte Progenitor Cultures and Quantification of Oligodendrogenesis Using Dual-infrared Fluorescence Scanning
Published on: February 17, 2016
07:45An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
GPCRs Regulate Adenylyl Cylase Activity
Huntington Disease l: Introduction
GPCR Desensitization
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters